MONTREAL, August 8, 2023 – Cordex Biologics Inc., an ExCellThera Company, announced today the recent publication in Blood Advances from the American Society of Hematology of results from a safety and efficacy retrospective analysis comparing outcomes of patients treated with UM171-expanded Cell Therapy in a Phase 1/2 trial to those treated with matched unrelated donor peripheral blood and cord blood stem cell transplants. In this real-world analysis using matched-controlled data from the CIBMTR® (Center for International Blood and Marrow Transplant Research®), UM171-expanded Cell Therapy demonstrated improved outcomes compared to matched unrelated donor (MUD) peripheral blood stem cell (PBSC) transplants and cord blood (CB), including overall survival (OS), progression-free survival (PFS), and graft-versus-host disease (GVHD) and relapse-free survival (GRFS). The publication is available at https://doi.org/10.1182/bloodadvances.2023010599.
“This matched-controlled real-world analysis published in Blood Advances strongly suggests that UM171-expanded Cell Therapy improves key long-term clinical outcomes for patients suffering from blood cancers who need a matched unrelated donor or a cord blood transplant. More specifically, we observed significant reductions in transplant related mortality and improvement in graft-versus-host disease and relapse-free survival, or GRFS, over these two graft sources” said Guy Sauvageau, MD, PhD, Founder and Chief Scientific Officer.
“This is an important achievement for Cordex Biologics and its most advanced therapy,” said Pierre Caudrelier, MD, Chief Medical Officer. “With a significant GRFS hazard ratio (HR) below 0.3 and 0.4 in favour of UM171-expanded Cell Therapy versus standard of care matched unrelated donor or cord blood transplants, respectively, UM171-expanded Cell Therapy can offer clinically meaningful benefits over common graft sources.”
Overall, 137 CIBMTR control patients and 22 UM171-expanded Cell Therapy Phase 1/2 trial patients were included in the study. Selected results are shown in the table below.
About Cordex Biologics and UM171-expanded Cell Therapy
Cordex Biologics Inc., an ExCellThera company, develops UM171-expanded Cell Therapy and other UM171-expanded cord blood-based cell therapies. UM171-expanded Cell Therapy has been evaluated in over 100 patients to treat hematologic malignancies in clinical trials in the United States, Europe and Canada. UM171-expanded Cell Therapy has received orphan drug designation and regenerative medicine advanced therapy (RMAT) designation from the FDA as well as orphan medicinal product designation, advanced therapy medicinal product (ATMP) classification and priority medicines (PRIME) designation from the EMA. For additional information, visit cordexbio.com, and follow us on LinkedIn.
UM171-expanded Cell Therapy is an investigational cell therapy, and its safety and efficacy have not been established by the FDA, EMA, Health Canada or any other health authority.
ExCellThera is a world leader in blood stem cell expansion and rejuvenation. ExCellThera’s proprietary EnhanceTM platform for cell expansion and rejuvenation is designed to deliver a greater dose of functional therapeutic stem cells by expanding HSCs from any source and counteracting the effects of culture or gene editing induced stress. ExCellThera partners with biopharma companies and institutions to help them develop best-in-class cell and gene therapies by leveraging the technologies and processes that form the EnhanceTM platform, including proprietary molecule UM171 which has a first-in-class mechanism of action for ex vivo expansion and rejuvenation of HSCs. For additional information, visit excellthera.com, and follow us on LinkedIn.